276 related articles for article (PubMed ID: 27912207)
1. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
[TBL] [Abstract][Full Text] [Related]
3. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
4. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
6. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Aversa M; Porter S; Granton J
Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
[TBL] [Abstract][Full Text] [Related]
8. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
Duo-Ji MM; Long ZW
Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
[TBL] [Abstract][Full Text] [Related]
11. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
Dong S; Guo X; Wang H; Sun C
Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
Kuntz M; Leiva-Juarez MM; Luthra S
Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
[TBL] [Abstract][Full Text] [Related]
13. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
14. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
Omura J; Makanji Y; Tanabe N; Yu DY; Tan JY; Lim S; Kouhkamari MH; Casorso J; Wu DB; Bloomfield P
Pulm Ther; 2023 Dec; 9(4):511-526. PubMed ID: 37991630
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
[TBL] [Abstract][Full Text] [Related]
17. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
Vergouwen MD; Algra A; Rinkel GJ
Stroke; 2012 Oct; 43(10):2671-6. PubMed ID: 22871682
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
20. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]